The Experts below are selected from a list of 246 Experts worldwide ranked by ideXlab platform
Arjan Vissink - One of the best experts on this subject based on the ideXlab platform.
-
abatacept treatment of patients with primary sjogren s syndrome results in a decrease of germinal centres in salivary Gland Tissue
Clinical and Experimental Rheumatology, 2017Co-Authors: Erlin A Haacke, Arjan Vissink, Bert Van Der Vegt, Hendrika Bootsma, Petra M Meiners, Fred K L Spijkervet, Frans G M KroeseAbstract:Objective. The aim of this study was to assess the histopathological changes in parotid Gland Tissue of primary Sjogren's syndrome (pSS) patients treated with abatacept. Methods. In all 15 pSS patients included in the open-label Active Sjogren Abatacept Pilot (ASAP, 8 abatacept infusions) study parotid Gland biopsies were taken before treatment and at 24 weeks of follow up. Biopsies were analysed for pSS-related histopathological features and placed in context of clinical responsiveness as assessed with EULAR Sjogren's syndrome disease activity index (ESSDAI). Results. Abatacept treatment resulted in a decrease of germinal centres (GCs)/mm(2) (p=0.173). Number of GCs/mm(2) at baseline was associated with response in the Glandular domain of ESSDAI (Spearman.=0.644, p=0.009). Abatacept treatment did not reduce focus score, lymphoepithelial lesions, area of lymphocytic infiltrate, amount of CD21(+) networks of follicular dendritic cells, and numbers of CD3(+) T-cells or CD20(+) B-cells. Number of IgM plasma cells/mm(2) increased (p=0.041), while numbers of IgA and IgG plasma cells/mm(2) were unaffected during abatacept treatment. Conclusion. Abatacept affects formation of GCs of pSS patients in parotid Glands, which is dependent on co-stimulation of activated follicular-helper-T-cells. Herewith, local formation of (autoreactive) memory B-cells is inhibited. Presence of GCs at baseline predicts responsiveness to abatacept in the ESSDAI Glandular domain.
-
need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary Gland Tissue of patients with primary sjogren s syndrome
Annals of the Rheumatic Diseases, 2016Co-Authors: Arjan Vissink, Konstantina Delli, Erlin A Haacke, Stephan Ihrler, Bert Van Der Vegt, Hendrika BootsmaAbstract:We have read with great interest the letter to the editor by van Roon et al 1 commenting on our paper ‘Towards personalised treatment in primary Sjogren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment’.2 The authors argue that there is a need for standardisation of the histopathological characteristics of salivary Gland Tissue of patients with primary Sjogren's syndrome (pSS), in general, and of the presence of germinal centres (GCs), in particular. We fully agree with van Roon et al 1 and other authors about the need for consensus guidelines to standardise the histopathological evaluation of salivary Gland biopsies in patients with pSS.3 A standardised scoring system may facilitate prognostication and stratification of patients with pSS and is needed for a valid evaluation of various clinical trials.3 In particular, histological definition of GCs in salivary Gland Tissue is warranted, since these structures can be difficult to detect in diagnostic H&E-stained Tissue sections. Detection of GCs in the periductal lymphoid infiltrates of the salivary Glands is clinically relevant, because the presence of these structures is associated with more severe disease.4 Importantly, the presence of GCs in minor salivary Gland biopsies has been postulated to be a predictor of patients who are at risk of lymphoma development.5 …
-
clinical management of salivary Gland hypofunction and xerostomia in head and neck cancer patients successes and barriers
International Journal of Radiation Oncology Biology Physics, 2010Co-Authors: Arjan Vissink, Kirsten H Limesand, Siri Beier Jensen, Linda S. Elting, Robert P Coppes, James B Mitchell, Bruce J Baum, Johannes A. Langendijk, Mary E ReylandAbstract:The most significant long-term complication of radiotherapy in the head-and-neck region is hyposalivation and its related complaints, particularily xerostomia. This review addresses the pathophysiology underlying irradiation damage to salivary Gland Tissue, the consequences of radiation injury, and issues contributing to the clinical management of salivary Gland hypofunction and xerostomia. These include ways to (1) prevent or minimize radiation injury of salivary Gland Tissue, (2) manage radiation-induced hyposalivation and xerostomia, and (3) restore the function of salivary Gland Tissue damaged by radiotherapy.
Erlin A Haacke - One of the best experts on this subject based on the ideXlab platform.
-
abatacept treatment of patients with primary sjogren s syndrome results in a decrease of germinal centres in salivary Gland Tissue
Clinical and Experimental Rheumatology, 2017Co-Authors: Erlin A Haacke, Arjan Vissink, Bert Van Der Vegt, Hendrika Bootsma, Petra M Meiners, Fred K L Spijkervet, Frans G M KroeseAbstract:Objective. The aim of this study was to assess the histopathological changes in parotid Gland Tissue of primary Sjogren's syndrome (pSS) patients treated with abatacept. Methods. In all 15 pSS patients included in the open-label Active Sjogren Abatacept Pilot (ASAP, 8 abatacept infusions) study parotid Gland biopsies were taken before treatment and at 24 weeks of follow up. Biopsies were analysed for pSS-related histopathological features and placed in context of clinical responsiveness as assessed with EULAR Sjogren's syndrome disease activity index (ESSDAI). Results. Abatacept treatment resulted in a decrease of germinal centres (GCs)/mm(2) (p=0.173). Number of GCs/mm(2) at baseline was associated with response in the Glandular domain of ESSDAI (Spearman.=0.644, p=0.009). Abatacept treatment did not reduce focus score, lymphoepithelial lesions, area of lymphocytic infiltrate, amount of CD21(+) networks of follicular dendritic cells, and numbers of CD3(+) T-cells or CD20(+) B-cells. Number of IgM plasma cells/mm(2) increased (p=0.041), while numbers of IgA and IgG plasma cells/mm(2) were unaffected during abatacept treatment. Conclusion. Abatacept affects formation of GCs of pSS patients in parotid Glands, which is dependent on co-stimulation of activated follicular-helper-T-cells. Herewith, local formation of (autoreactive) memory B-cells is inhibited. Presence of GCs at baseline predicts responsiveness to abatacept in the ESSDAI Glandular domain.
-
need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary Gland Tissue of patients with primary sjogren s syndrome
Annals of the Rheumatic Diseases, 2016Co-Authors: Arjan Vissink, Konstantina Delli, Erlin A Haacke, Stephan Ihrler, Bert Van Der Vegt, Hendrika BootsmaAbstract:We have read with great interest the letter to the editor by van Roon et al 1 commenting on our paper ‘Towards personalised treatment in primary Sjogren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment’.2 The authors argue that there is a need for standardisation of the histopathological characteristics of salivary Gland Tissue of patients with primary Sjogren's syndrome (pSS), in general, and of the presence of germinal centres (GCs), in particular. We fully agree with van Roon et al 1 and other authors about the need for consensus guidelines to standardise the histopathological evaluation of salivary Gland biopsies in patients with pSS.3 A standardised scoring system may facilitate prognostication and stratification of patients with pSS and is needed for a valid evaluation of various clinical trials.3 In particular, histological definition of GCs in salivary Gland Tissue is warranted, since these structures can be difficult to detect in diagnostic H&E-stained Tissue sections. Detection of GCs in the periductal lymphoid infiltrates of the salivary Glands is clinically relevant, because the presence of these structures is associated with more severe disease.4 Importantly, the presence of GCs in minor salivary Gland biopsies has been postulated to be a predictor of patients who are at risk of lymphoma development.5 …
Hendrika Bootsma - One of the best experts on this subject based on the ideXlab platform.
-
abatacept treatment of patients with primary sjogren s syndrome results in a decrease of germinal centres in salivary Gland Tissue
Clinical and Experimental Rheumatology, 2017Co-Authors: Erlin A Haacke, Arjan Vissink, Bert Van Der Vegt, Hendrika Bootsma, Petra M Meiners, Fred K L Spijkervet, Frans G M KroeseAbstract:Objective. The aim of this study was to assess the histopathological changes in parotid Gland Tissue of primary Sjogren's syndrome (pSS) patients treated with abatacept. Methods. In all 15 pSS patients included in the open-label Active Sjogren Abatacept Pilot (ASAP, 8 abatacept infusions) study parotid Gland biopsies were taken before treatment and at 24 weeks of follow up. Biopsies were analysed for pSS-related histopathological features and placed in context of clinical responsiveness as assessed with EULAR Sjogren's syndrome disease activity index (ESSDAI). Results. Abatacept treatment resulted in a decrease of germinal centres (GCs)/mm(2) (p=0.173). Number of GCs/mm(2) at baseline was associated with response in the Glandular domain of ESSDAI (Spearman.=0.644, p=0.009). Abatacept treatment did not reduce focus score, lymphoepithelial lesions, area of lymphocytic infiltrate, amount of CD21(+) networks of follicular dendritic cells, and numbers of CD3(+) T-cells or CD20(+) B-cells. Number of IgM plasma cells/mm(2) increased (p=0.041), while numbers of IgA and IgG plasma cells/mm(2) were unaffected during abatacept treatment. Conclusion. Abatacept affects formation of GCs of pSS patients in parotid Glands, which is dependent on co-stimulation of activated follicular-helper-T-cells. Herewith, local formation of (autoreactive) memory B-cells is inhibited. Presence of GCs at baseline predicts responsiveness to abatacept in the ESSDAI Glandular domain.
-
need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary Gland Tissue of patients with primary sjogren s syndrome
Annals of the Rheumatic Diseases, 2016Co-Authors: Arjan Vissink, Konstantina Delli, Erlin A Haacke, Stephan Ihrler, Bert Van Der Vegt, Hendrika BootsmaAbstract:We have read with great interest the letter to the editor by van Roon et al 1 commenting on our paper ‘Towards personalised treatment in primary Sjogren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment’.2 The authors argue that there is a need for standardisation of the histopathological characteristics of salivary Gland Tissue of patients with primary Sjogren's syndrome (pSS), in general, and of the presence of germinal centres (GCs), in particular. We fully agree with van Roon et al 1 and other authors about the need for consensus guidelines to standardise the histopathological evaluation of salivary Gland biopsies in patients with pSS.3 A standardised scoring system may facilitate prognostication and stratification of patients with pSS and is needed for a valid evaluation of various clinical trials.3 In particular, histological definition of GCs in salivary Gland Tissue is warranted, since these structures can be difficult to detect in diagnostic H&E-stained Tissue sections. Detection of GCs in the periductal lymphoid infiltrates of the salivary Glands is clinically relevant, because the presence of these structures is associated with more severe disease.4 Importantly, the presence of GCs in minor salivary Gland biopsies has been postulated to be a predictor of patients who are at risk of lymphoma development.5 …
Bert Van Der Vegt - One of the best experts on this subject based on the ideXlab platform.
-
abatacept treatment of patients with primary sjogren s syndrome results in a decrease of germinal centres in salivary Gland Tissue
Clinical and Experimental Rheumatology, 2017Co-Authors: Erlin A Haacke, Arjan Vissink, Bert Van Der Vegt, Hendrika Bootsma, Petra M Meiners, Fred K L Spijkervet, Frans G M KroeseAbstract:Objective. The aim of this study was to assess the histopathological changes in parotid Gland Tissue of primary Sjogren's syndrome (pSS) patients treated with abatacept. Methods. In all 15 pSS patients included in the open-label Active Sjogren Abatacept Pilot (ASAP, 8 abatacept infusions) study parotid Gland biopsies were taken before treatment and at 24 weeks of follow up. Biopsies were analysed for pSS-related histopathological features and placed in context of clinical responsiveness as assessed with EULAR Sjogren's syndrome disease activity index (ESSDAI). Results. Abatacept treatment resulted in a decrease of germinal centres (GCs)/mm(2) (p=0.173). Number of GCs/mm(2) at baseline was associated with response in the Glandular domain of ESSDAI (Spearman.=0.644, p=0.009). Abatacept treatment did not reduce focus score, lymphoepithelial lesions, area of lymphocytic infiltrate, amount of CD21(+) networks of follicular dendritic cells, and numbers of CD3(+) T-cells or CD20(+) B-cells. Number of IgM plasma cells/mm(2) increased (p=0.041), while numbers of IgA and IgG plasma cells/mm(2) were unaffected during abatacept treatment. Conclusion. Abatacept affects formation of GCs of pSS patients in parotid Glands, which is dependent on co-stimulation of activated follicular-helper-T-cells. Herewith, local formation of (autoreactive) memory B-cells is inhibited. Presence of GCs at baseline predicts responsiveness to abatacept in the ESSDAI Glandular domain.
-
need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary Gland Tissue of patients with primary sjogren s syndrome
Annals of the Rheumatic Diseases, 2016Co-Authors: Arjan Vissink, Konstantina Delli, Erlin A Haacke, Stephan Ihrler, Bert Van Der Vegt, Hendrika BootsmaAbstract:We have read with great interest the letter to the editor by van Roon et al 1 commenting on our paper ‘Towards personalised treatment in primary Sjogren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment’.2 The authors argue that there is a need for standardisation of the histopathological characteristics of salivary Gland Tissue of patients with primary Sjogren's syndrome (pSS), in general, and of the presence of germinal centres (GCs), in particular. We fully agree with van Roon et al 1 and other authors about the need for consensus guidelines to standardise the histopathological evaluation of salivary Gland biopsies in patients with pSS.3 A standardised scoring system may facilitate prognostication and stratification of patients with pSS and is needed for a valid evaluation of various clinical trials.3 In particular, histological definition of GCs in salivary Gland Tissue is warranted, since these structures can be difficult to detect in diagnostic H&E-stained Tissue sections. Detection of GCs in the periductal lymphoid infiltrates of the salivary Glands is clinically relevant, because the presence of these structures is associated with more severe disease.4 Importantly, the presence of GCs in minor salivary Gland biopsies has been postulated to be a predictor of patients who are at risk of lymphoma development.5 …
Mingfeng Jiang - One of the best experts on this subject based on the ideXlab platform.
-
metabolomic profiles in yak mammary Gland Tissue during the lactation cycle
PLOS ONE, 2019Co-Authors: Mingfeng JiangAbstract:The yak is one of the most important domestic animals in Tibetan life for providing basic resources such as milk, meat and transportation. Although yak milk production is not elevated, yak milk is superior to dairy cow milk in nutrient composition (protein and fat). However, the understanding of the metabolic mechanisms of yak mammary Gland Tissue during the lactation cycle remains elusive. In this study, GC-MS-based metabolomics was employed to study the metabolic variations in the yak mammary Gland during the lactation cycle (pregnancy, lactation and dry period). Twenty-nine metabolites were up or downregulated during the lactation period. Compared to the dry period, during the lactation period the levels of oxalic acid were upregulated, while glycine and uridine were downregulated. Thirty-seven pathways were obtained when the 29 differential metabolites were imported into the KEGG pathway analysis. The most impacted pathways during the lactation cycle were glycine, serine and threonine metabolism; alanine, aspartate and glutamate metabolism; TCA cycle; glyoxylate and dicarboxylate metabolism; and pyrimidine metabolism. Our results provide important insights into the metabolic events involved in yak mammary Gland development, lactogenesis and lactation, which can guide further research to improve milk yield and enhance the constituents of yak milk.